[Pubmed] Differences in IgG autoantibody Fab glycosylation across autoimmune diseases

Intégration des publications parues sur PUBMED
Répondre
Avatar du membre

Auteur du sujet
RSS-Bot
Ami(e) de Diamant
Ami(e) de Diamant
Messages : 2983
Enregistré le : 31 mai 2020 09:57
3
Zodiaque :
Âge : 20
Contact :
    Windows 10 Firefox

[Pubmed] Differences in IgG autoantibody Fab glycosylation across autoimmune diseases

Message par RSS-Bot »


J Allergy Clin Immunol. 2023 Jan 27:S0091-6749(23)00091-X. doi: 10.1016/j.jaci.2022.10.035. Online ahead of print.

ABSTRACT

BACKGROUND: Increased prevalence of autoantibody Fab glycosylation has been demonstrated for several autoimmune diseases.

OBJECTIVE: To study if elevated Fab glycosylation is a common feature of autoimmunity, we investigated Fab glycosylation levels on serum IgG and its subclasses for autoantibodies associated with a range of different B cell-mediated autoimmune diseases, including rheumatoid arthritis, myasthenia gravis subtypes, pemphigus vulgaris, ANCA-associated vasculitis, systemic lupus erythematosus, anti-GBM glomerulonephritis, thrombotic thrombocytopenic purpura and Guillain-Barré syndrome.

METHODS: The level of Fab glycosylated IgG antibodies was assessed by lectin affinity chromatography and autoantigen-specific immunoassays.

RESULTS: In six out of ten autoantibody responses, in five out of eight diseases, we found increased levels of Fab glycosylation on IgG autoantibodies that varied from 86% in RA to 26% in SLE. Elevated autoantibody Fab glycosylation was not restricted to IgG4, which is known to be prone to Fab glycosylation, but also present in IgG1. When autoimmune diseases with a chronic disease course were compared with more acute autoimmune illnesses, increased Fab glycosylation was restricted to the chronic diseases. As a proxy for chronic autoantigen exposure, we determined Fab glycosylation levels on antibodies to common latent herpes viruses, as well as to gp120 in chronically HIV-1-infected individuals. Immunity to these viral antigens was not associated with increased Fab glycosylation levels, indicating that chronic antigen-stimulation as such does not lead to increased Fab glycosylation levels.

CONCLUSION: Our data indicate that in chronic but not acute B cell-mediated autoimmune diseases disease-specific autoantibodies are enriched for Fab glycans.

PMID:36716825 | DOI:10.1016/j.jaci.2022.10.035


Source: https://pubmed.ncbi.nlm.nih.gov/3671682 ... t6+86293ac
Si vous appréciez notre travail, merci de nous soutenir un petit don en cliquant ICI

Pour obtenir la traduction en français,
cliquez sur le bouton situé dans la barre des menus en haut de cette page 

Image


Pour les donateurs, si cet article vous intéresse, nous pouvons faire l’acquisition d'un tiré-à-part.
Merci d'en faire la demande sur association.amis-modo@myasthenie.com


Bonne lecture...
Répondre

Retourner vers « Echos de la recherche »